MX359315B - Vacuna de adn para usarse en pacientes con cancer pancreatico. - Google Patents
Vacuna de adn para usarse en pacientes con cancer pancreatico.Info
- Publication number
- MX359315B MX359315B MX2014015977A MX2014015977A MX359315B MX 359315 B MX359315 B MX 359315B MX 2014015977 A MX2014015977 A MX 2014015977A MX 2014015977 A MX2014015977 A MX 2014015977A MX 359315 B MX359315 B MX 359315B
- Authority
- MX
- Mexico
- Prior art keywords
- pancreatic cancer
- cancer patients
- dna vaccine
- salmonella
- present
- Prior art date
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- 201000002528 pancreatic cancer Diseases 0.000 title 1
- 208000008443 pancreatic carcinoma Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241000607142 Salmonella Species 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 102000053602 DNA Human genes 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una cepa mutante atenuada de Salmonella que comprende una molécula de ADN recombinante que codifica para una proteína receptora del VEGF. En particular, la presente invención se relaciona con el uso de la cepa mutante atenuada de Salmonella en la inmunoterapia del cáncer. Una vacuna VXM01 de ADN que comprende la cepa atenuada de Salmonella typhi Ty21a transformada por un plásmido que contiene un ADN que codifica para la proteína VEGFR-2 de SEQ ID NO 1, en donde el plásmido es un ADN plasmídico de 7580 pb, que comprende el ADNc de VEGFR-2 que está bajo el control del promotor de CMV, el gen de resistencia a la kanamicina, y el ori de pMB1, y se designa como pVAX10.VR2-1, para usarse en inmunoterapia contra cáncer, en donde la dosis individual de la vacuna es 1 x 109 UFC o menos de 1 x 109 UFC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12004995 | 2012-07-05 | ||
| PCT/EP2013/001882 WO2014005683A1 (en) | 2012-07-05 | 2013-06-26 | Dna vaccine for use in pancreatic cancer patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014015977A MX2014015977A (es) | 2015-03-20 |
| MX359315B true MX359315B (es) | 2018-09-25 |
Family
ID=48741047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014015977A MX359315B (es) | 2012-07-05 | 2013-06-26 | Vacuna de adn para usarse en pacientes con cancer pancreatico. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9415098B2 (es) |
| EP (2) | EP3603664A1 (es) |
| JP (1) | JP6325534B2 (es) |
| KR (1) | KR102090612B1 (es) |
| CN (1) | CN104519908B (es) |
| AU (2) | AU2013286335B2 (es) |
| BR (1) | BR112014033046A2 (es) |
| CA (1) | CA2877938A1 (es) |
| DK (1) | DK2869836T3 (es) |
| ES (1) | ES2752141T3 (es) |
| HU (1) | HUE046138T2 (es) |
| IL (1) | IL236049B (es) |
| LT (1) | LT2869836T (es) |
| MX (1) | MX359315B (es) |
| PL (1) | PL2869836T3 (es) |
| RU (1) | RU2636348C2 (es) |
| SG (1) | SG11201500054QA (es) |
| SI (1) | SI2869836T1 (es) |
| WO (1) | WO2014005683A1 (es) |
| ZA (1) | ZA201409156B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX359315B (es) * | 2012-07-05 | 2018-09-25 | Vaximm Ag | Vacuna de adn para usarse en pacientes con cancer pancreatico. |
| RU2018101722A (ru) * | 2015-06-18 | 2019-07-18 | Факсимм Аг | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии |
| US20180153976A1 (en) | 2015-06-18 | 2018-06-07 | Vaximm Ag | Novel cmv pp65 targeting dna vaccine for cancer immunotherapy |
| WO2018011289A1 (en) * | 2016-07-13 | 2018-01-18 | Vaximm Ag | Process for the production of a dna vaccine for cancer immunotherapy |
| KR102337986B1 (ko) | 2016-10-07 | 2021-12-10 | 덴카 주식회사 | 질화 붕소 덩어리 형상의 입자, 그 제조 방법 및 이를 이용한 열전도 수지 조성물 |
| EP3530614A4 (en) | 2016-10-21 | 2020-04-29 | Denka Company Limited | SPHERICAL BORNITRIDE FINE POWDER, METHOD FOR THE PRODUCTION THEREOF AND HEAT-CONDUCTING RESIN COMPOSITION THEREFOR |
| KR20190082227A (ko) * | 2016-11-04 | 2019-07-09 | 백심 아게 | 병용 요법용 wt1 표적화 dna 백신 |
| BR112019016925A2 (pt) * | 2017-02-17 | 2020-05-26 | Vaximm Ag | Cepa atenuada de salmonella |
| RU2019132253A (ru) | 2017-03-17 | 2021-04-19 | Факсимм Аг | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака |
| WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
| CN118147029A (zh) | 2018-07-11 | 2024-06-07 | 阿克蒂姆治疗有限公司 | 工程化的免疫刺激性细菌菌株及其用途 |
| AU2019334131A1 (en) | 2018-09-05 | 2021-03-04 | NEC Oncolmmunity AS | Neoantigen targeting DNA vaccine for combination therapy |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| KR20220128638A (ko) | 2020-01-13 | 2022-09-21 | 백심 아게 | 항생제와 조합되는 살모넬라-기반의 dna 백신 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US20220226465A1 (en) | 2021-01-18 | 2022-07-21 | ConserV Bioscience | Coronavirus Immunogenic Compositions, Methods and Uses Thereof |
| EP4444329A1 (en) * | 2021-12-09 | 2024-10-16 | Prokarium Limited | Combination cancer therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR930001382B1 (ko) | 1990-09-05 | 1993-02-27 | 보령신약 주식회사 | 경구용 장티프스 생균백신 및 그의 제조방법 |
| US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| CN101274098A (zh) | 2003-05-30 | 2008-10-01 | 健泰科生物技术公司 | 利用抗-vegf抗体的治疗 |
| BR112014015706A2 (pt) | 2011-12-22 | 2020-10-27 | Vaximm Ag | método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a |
| MX359315B (es) * | 2012-07-05 | 2018-09-25 | Vaximm Ag | Vacuna de adn para usarse en pacientes con cancer pancreatico. |
-
2013
- 2013-06-26 MX MX2014015977A patent/MX359315B/es active IP Right Grant
- 2013-06-26 EP EP19194049.3A patent/EP3603664A1/en not_active Withdrawn
- 2013-06-26 WO PCT/EP2013/001882 patent/WO2014005683A1/en active Application Filing
- 2013-06-26 KR KR1020157002939A patent/KR102090612B1/ko active IP Right Grant
- 2013-06-26 BR BR112014033046A patent/BR112014033046A2/pt not_active Application Discontinuation
- 2013-06-26 DK DK13732833T patent/DK2869836T3/da active
- 2013-06-26 CN CN201380035905.6A patent/CN104519908B/zh active Active
- 2013-06-26 US US14/409,434 patent/US9415098B2/en active Active
- 2013-06-26 EP EP13732833.2A patent/EP2869836B1/en active Active
- 2013-06-26 HU HUE13732833A patent/HUE046138T2/hu unknown
- 2013-06-26 LT LT13732833T patent/LT2869836T/lt unknown
- 2013-06-26 JP JP2015518890A patent/JP6325534B2/ja active Active
- 2013-06-26 RU RU2015103758A patent/RU2636348C2/ru not_active IP Right Cessation
- 2013-06-26 PL PL13732833T patent/PL2869836T3/pl unknown
- 2013-06-26 CA CA2877938A patent/CA2877938A1/en active Pending
- 2013-06-26 AU AU2013286335A patent/AU2013286335B2/en active Active
- 2013-06-26 SG SG11201500054QA patent/SG11201500054QA/en unknown
- 2013-06-26 ES ES13732833T patent/ES2752141T3/es active Active
- 2013-06-26 SI SI201331605T patent/SI2869836T1/sl unknown
-
2014
- 2014-12-03 IL IL236049A patent/IL236049B/en not_active IP Right Cessation
- 2014-12-12 ZA ZA2014/09156A patent/ZA201409156B/en unknown
-
2016
- 2016-05-18 US US15/158,387 patent/US20160250311A1/en not_active Abandoned
-
2017
- 2017-11-08 AU AU2017258877A patent/AU2017258877B2/en active Active
-
2018
- 2018-05-31 US US15/994,766 patent/US10293037B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014015977A (es) | Vacuna de adn para usarse en pacientes con cancer pancreatico. | |
| MX2016007939A (es) | Nueva vacuna de adn dirigida contra msln para la inmunoterapia de cancer. | |
| MX2015014851A (es) | Vacuna de adn que dirige wt-1 novedosa para inmunoterapia del cancer. | |
| PH12015500390B1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| TN2014000438A1 (en) | Anti-fcrn antibodies | |
| ZA201503097B (en) | Production of recombinant vaccine in e. coli by enzymatic conjugation | |
| MX2018012166A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| NZ630542A (en) | Methods of treating a tauopathy | |
| AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
| MX2020010693A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
| IN2014KN03063A (es) | ||
| PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
| MX2014006630A (es) | Vacuna a base toxina clostridium difficile. | |
| EA201390955A1 (ru) | Слитый белок robo1-fc для применения в лечении гепатокарциномы | |
| MX368474B (es) | Uso de benralizumab para mejorar síntomas de asma. | |
| MX2016001691A (es) | Moleculas de union al receptor bag3 para uso como un medicamento. | |
| MX2019011026A (es) | Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer. | |
| MX2013003168A (es) | Anticuerpo contra ephrin b2 y su uso. | |
| MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
| WO2013167842A3 (fr) | Composition immunogène comprenant un peptide dérivé du vegf et ses utilisations | |
| MX2019008148A (es) | Uso de peptidos glp-1 de accion prolongada. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |